ProCE Banner Activity

CE / CME

Immunotherapy Approaches for HCC

Multimedia
Watch this on-demand webcast featuring an expert presentation on the use of checkpoint inhibitors in patients with advanced hepatocellular carcinoma. This program specifically focuses on educating hepatologists, medical oncologists, and other members of the multidisciplinary care team.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: June 21, 2021

Expiration: June 20, 2022

No longer available for credit.

Share

Faculty

David Kaplan

David Kaplan, MD, MSc

Assistant Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Director of Hepatology
Gastroenterology Section
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Thomas B. Karasic

Thomas B. Karasic, MD

Physician Leader, Developmental Therapeutics
Assistant Professor of Medicine
Division of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Target Audience

This program is intended for hepatologists and other healthcare professionals who care for patients with HCC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, comorbid liver diseases, and patient characteristics and preferences
  • Review recent therapeutic advances and FDA approvals for the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Evaluate clinical data on the use of novel systemic therapies for patients with relapsed/refractory advanced HCC and integrate this information into clinical practice, taking into consideration the available clinical evidence, preexisting cirrhosis and other liver diseases, known agent toxicity/tolerability profiles, expert recommendations, and patient preferences
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC while also managing comorbid liver diseases
  • Plan strategies and care plans for coordination of treatment of HCC to maximize benefit for local and systemic therapies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

David Kaplan, MD, MSc

Assistant Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Director of Hepatology
Gastroenterology Section
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

David Kaplan, MD, MSc, has disclosed that he has received consulting fees from Exelixis and funds for research support from Bayer and Gilead Sciences.

Thomas B. Karasic, MD

Physician Leader, Developmental Therapeutics
Assistant Professor of Medicine
Division of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Thomas Karasic, MD, has disclosed that he has received consulting fees from Exelixis, Incyte, and Pfizer and funds for research support from Bristol-Myers Squibb and Lilly.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, RNP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-124-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 21, 2021, through June 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners in their clinical use of optimal HCC immunotherapy options.